
==== Front
J Cardiothorac Surg
J Cardiothorac Surg
Journal of Cardiothoracic Surgery
1749-8090
BioMed Central London

2994
10.1186/s13019-024-02994-3
Research
The protective effect of Ghrelin peptide on doxorubicin hydrochloride induced heart failure in rats
Peng Ying 1
Zhang Ping 2
Zou Pengtao 1
Zhou Yuxuan 1
Shao Liang shaoliang5201@126.com

1
1 grid.415002.2 0000 0004 1757 8108 Department of Cardiology, Jiangxi Provincial People’s Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006 Jiangxi Province China
2 grid.415002.2 0000 0004 1757 8108 Department of Neurology, Jiangxi Provincial People’s Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006 Jiangxi Province China
2 9 2024
2 9 2024
2024
19 50817 4 2024
13 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

To investigate the protective effect and mechanism of Ghrelin on Doxorubicin (Dox) hydrochloride induced heart failure (HF) and myocardial injury in rats.

Methods

45 rats were randomly divided into control group, HF group and Ghrelin group. Dox hydrochloride was injected intraperitoneally to establish the model of HF in rats of HF group and Ghrelin group. Rats in the Ghrelin group were given intraperitoneal injection of Ghrelin twice a day, and rats in the HF group and control group were given equal volume of normal saline for a total of 6 weeks. The changes of echocardiography, cardiac hemodynamics, myocardial histology and plasma inflammatory factors were observed.

Results

After the Ghrelin intervention, compared with the HF group, the left ventricular end-diastolic diameter (LVDD) and left ventricular end-systolic diameter (LVSD) in the Ghrelin group was markedly reduced (P < 0.05), and left ventricular ejection fraction (LVEF) was significantly increased (P < 0.05). Compared with HF group, the left ventricular systolic pressure (LVSP), maximum rate of increase in left ventricular pressure (+ dP/dtmax) and maximum rate of decrease in left ventricular pressure (− dP/dtmax) of Ghrelin group was remarkedly increased (P < 0.05), left ventricular diastolic pressure (LVDP) decreased (P < 0.05). In the Ghrelin group, the degree and extent of cardiomyocyte degeneration and necrosis were remarkedly reduced compared with the HF group. The levels of TNF-α and iNOS in Ghrelin group were notably lower than those in HF group (P < 0.05), the IL-10 level increased markedly (P < 0.05).

Conclusion

Ghrelin may reduce Dox-induced myocardial injury and improve cardiac function in rats by regulating inflammation and oxidative stress.

Keywords

Ghrelin polypeptide
Doxorubicin hydrochloride
Heart failure
Protection
Rats
the National Natural Science Foundation of ChinaNo.82260078, for Shao Liang issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Heart Failure (HF) is widespread in clinical practice, and the incidence is increasing, the annual treatment cost due to HF is also increasing. HF is an end-stage cardiac disease caused by the chronic progression of coronary heart disease, hypertension, heart valve diseases, myocardial infarction and other diseases [1]. According to worldwide statistics, nearly 1–2 out of every 100 people suffer from HF. With the progress of aging population, HF is increasing worldwide [2]. Chronic Heart Failure (CHF) has a higher incidence in clinical practice, and the life quality of patients is severely reduced due to complications such as reduced activity tolerance, lower limb oedema, and gastrointestinal and digestive stasis and oedema [3]. Among the causes of CHF, myocardial infarction is one of the more frequent ones [4]. The venous stasis will lead to oedema of many organs, resulting in eventual organ hypoplasia and serious impairment of normal physiological functions [5, 6]. Therefore, the search for factors or drugs that can reduce myocardial inflammation and improve cardiac function to counteract the cardiotoxicity induced by antineoplastic drug therapy is of great clinical significance to improve the therapeutic effect of oncology patients [7].

Doxorubicin (Dox) is a common broad-spectrum anti-tumor drug. During the synthesis of RNA and DNA, Dox is inserted into the DNA chain to destroy the synthesis process, thus playing a therapeutic role in destroying tumor cells and inhibiting the spread of tumor cells [8]. Although the drug has a wide range of clinical applications, it can be used in combination with other chemotherapy drugs to treat various tumor diseases. However, most studies have found that Dox has side effects such as myelosuppression, cardiotoxicity, and digestive reactions, with cardiotoxicity being one of the most serious side effects of anthracyclines [9]. The short-term use of the drug in large quantities can cause acute cardiac injury, mainly inflammation. The long-term application can also lead to irreversible chronic cardiac injury, and the most common ventricular remodeling is cardiomyocyte apoptosis, myocardial fibrosis and cardiac atrophy [10, 11]. Ghrelin was first discovered in 1999 by Japanese scientists Kojima et al. in the stomach cells of animal bodies, and its research has been increasing since then [12]. At first, it was only found that Ghrelin belongs to a kind of growth hormone secretagogues, which regulates energy metabolism of the organism [13]. In recent years, more researchers have found that Ghrelin’s role in the body goes beyond this, and that its role in cardiovascular and cerebrovascular diseases is also more extensive, and its cardiovascular protective effects have led to more possibilities for clinical application in many chronic and intractable diseases, such as coronary heart disease and HF [14]. It has been found that Growth Hormone Secretagogue Receptor (GHSR) has a wide distribution in living organisms, including cardiac cells, blood vessel wall cells, and the organs of Ghrelin secretion are not only the digestive organs such as the stomach, small intestine, colon, pancreas [15]. Ghrelin is also secreted in the hypothalamus, pituitary gland, thyroid gland and adrenal gland, suggesting that Ghrelin has a certain amount of secretion in the body and has a wide range of ligands. It has been found that Ghrelin binds to specific sites in cardiomyocytes, inhibits apoptosis and myocardial remodeling. It has also been observed that Ghrelin protects cardiomyocytes against acute infarction myocardial tissue remodeling by inhibiting the synthesis of collagenous substances and inhibiting the production of inflammatory substances and the activation of inflammatory mediators, such as TNF-α in the tissue [16]. Studies have shown that Ghrelin can increase myocardial contractility, dilate blood vessels and protect the formation of heart failure after myocardial infarction [14]. Further studies have shown that Ghrelin and its receptor GHSR-la can be expressed in the heart and have a high affinity with the binding site on the heart [17, 18]. This suggested that the cardiovascular protective effect of Ghrelin exists independently of growth hormone, but its specific cellular and molecular mechanisms have not been fully clarified. In this study, the protective effect of Ghrelin on Dox induced myocardial injury and HF in rats was investigated to explore the protective effect and possible mechanism of Ghrelin in drug-induced cardiomyopathy, filling the gap of the effect of Ghrelin on heart failure.

Materials and methods

Reagents and equipment

The ultrasound machine and ultrasound probe for cardiac examination of animals were Visual Sonics, Canada, Dox hydrochloride was purchased from Pfizer Co. CM1900 frozen microtome was Leica, Germany. Enzyme-labeled apparatus (Multiskan SkyHigh) was Thermo, Finland. The TNF-α, IL-10 and iNOS ELISA kits purchased from Sigma Corporation, USA. The antibody was purchased from Abcam in the UK (TNF-α: ab6671; IL-10: ab34843; iNOS: ab15323;Actin: ab197345).

Animal grouping and model preparation

45 healthy adult 10-week-old male Sprague-Dawley rats, body weight 250–300 g. The rats were fed in separate cages, with 5 rats per cage. The rats were fed with ordinary feed formula, the room temperature of the animal house was controlled at about 24℃, and the rats were fed under light-dark cycle for 12 h.

45 rats were randomly divided into three groups. Rats in the HF group (n = 15) and Ghrelin group (n = 15) were intraperitoneally injected with Dox solution 2 mg/kg to establish an animal model of HF [19]. Control group (n = 10) rats were injected with an equal volume of 9% sodium chloride injection by the same method. The mental state, activity level, body mass and other general conditions of the rats were observed regularly during the experiment for 8 weeks. The rats were killed by decapitated method. Myocardial tissue was removed, partially treated with liquid nitrogen, and frozen at -80℃. The other part was incubated in paraformaldehyde.

Animal model evaluation

The rats were anesthetised by intraperitoneal injection of ketamine hydrochloride. The dose of rats in the control group was 100 mg/kg, and the dose of rats in the HF and Ghrelin groups was 70 mg/kg. After anesthesia, the hair was removed with 8% Na2S, and the fixed animals were examined by ascending echocardiography. All experimental data are completed by the same researcher to ensure the uniformity of research results. The study was approved by the Jiangxi Provincial People’s Hospital, the First Affiliated Hospital of Nanchang Medical College.

Echocardiographic examination

After modeling, the Ghrelin group was given 50 nmol/kg Ghrelin, the HF group and the control group were given equal volume normal saline, respectively, for a total of 6 weeks. They were given intraperitoneal injection at 8:00 am and 4:30 PM, respectively. After dry preconditioning, echocardiography was performed again in Ghrelin group, HF group and control group. Left ventricular end-diastolic diameter (LVDD), left ventricular end-systolic diameter (LVSD), left ventricular ejection fraction (LVEF), and left ventricular short axis shortening rate (LVFS) were measured and stored within 3 cardiac cycles.

Hemodynamic determination

The MPA-V multi-channel biological analysis system was used for detection. The rats were anaesthetized by intraperitoneal injection of ketamine hydrochloride and fixed in supine position. The rats’ neck fur was removed with 8% Na2S and disinfected, and the two common carotid arteries were exposed by making an incision in the middle of the neck. The right common carotid artery was isolated, the distal end was ligated and the proximal end was temporarily clamped off, then the polystyrene catheter filled with heparin saline was inserted retrogradely into the left ventricle. The pressure-volume curves were observed and the following hemodynamic parameters are recorded, including: left ventricular systolic pressure (LVSP), left ventricular diastolic pressure (LVDP), maximum rate of increase in left ventricular pressure (+ dP/dtmax) and maximum rate of decrease in left ventricular pressure (− dP/dtmax).

Myocardial HE staining

After the myocardial tissue was fixed with 4% paraformaldehyde for 72 h, conventional paraffin embedding, Sect. (5 μm thick), xylene dewaxing, and gradient alcohol hydration were performed. HE staining was performed according to kit instructions, and the staining degree was observed under microscope. After dyeing, gradient alcohol was dehydrated, xylene transparent, neutral gum was sealed, observed and photographed under an optical microscope.

Serum levels of TNF-α, IL-10 and iNOS

4 mL of blood was taken from rats at the time of execution, centrifuged at 1500 r/min for 10 min at 4℃, and the supernatant was extracted and frozen at -80℃ in a freezer. The serum TNF-α, IL-10 and iNOS levels were measured by ELISA.

Detection of protein expression levels

The total protein was extracted from the myocardial tissue. Protein concentration was measured and quantified by BCA method to prepare protein samples. The protein was separated by 10% SDS-polyacrylamide gel electrophoresis. The protein was transferred to PVDF membrane by semi-dry method, and the protein was placed in 5% skim milk powder and sealed at room temperature for 2 h, and the primary and secondary antibodies of the egg white were added to incubate for 2 h. Actin was used as the internal reference protein, and the relative expression of each protein was calculated by absorbance analysis after color development with the chromogenic solution.

Immunohistochemical staining

The paraffin sections of rat heart tissue were prepared, soaked in xylene for 10 min twice. The sections were deparaffinised in 100%, 95%, 85% and 75% ethanol to water, and the antigen was thermally repaired. 3% hydrogen peroxide was used for incubation for 10 min, and the primary antibodies of TNF-a, 1 L-10 and iNOS (1:200) were added dropwise at 4℃ overnight, and the HRP-labelled IgG (1:200) was added dropwise at 4℃. The sections were incubated at 37℃ for 30 min, and then the DAB work-up was added dropwise to develop the colors, and the sections were stained with hematoxylin, then dehydrated with ethanol (60-100%) and blocked. After staining with hematoxylin, gradient dehydration with ethanol (60-100%) was performed, and the slices were sealed. The samples were observed and photographed under a microscope. The samples were analyzed by Image Pro Plus 6.0 image analysis software to determine their mean optical density (MOD).

Statistical methods

SPSS 27.0 analysis software was applied. The measurement data conform to normal distribution and are expressed as (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\stackrel{-}{x}$$\end{document}± SD). T test was used to compare the mean of two samples, and one-way analysis of variance was used to compare the mean of multiple groups. LSD post hoc test was performed on the data. P < 0.05 indicating that the difference was statistically significant.

Results

Changes of echocardiography in rats after Ghrelin intervention

Figures 1 and 2 showed that all rats survived the modelling period. After 8 weeks of Dox modelling, the echocardiograms were performed before Ghrelin intervention. Compared with the control group, the left ventricle of rats in the HF group was apparently enlarged, ventricular wall activity was obviously weakened, LVDD and LVSD were increased (P < 0.05), and LVEF and LVFS were decreased (P < 0.05), indicating that HF was established. After the Ghrelin intervention, compared with the HF group, the LVDD and LVSD in the Ghrelin group was markedly reduced (P < 0.05), and LVEF was significantly increased (P < 0.05), indicating that Ghrelin significantly improved cardiac function in HF rats.

Fig. 1 The echocardiogram in different groups

Fig. 2 Comparison of echocardiographic parameters in different groups. Note: LVDD, Left ventricular end-diastolic diameter; LVSD, Left ventricular end-systolic diameter; LVEF, Left ventricular ejection fraction; LVFS, Left ventricular short axis shortening rate. Compared with HF group, * P < 0.05; Compared with control group, #P < 0.05

Results of hemodynamic detection

Figure 3 demonstrated that compared with control group, LVSP, +dP/dtmax, − dP/dtmax decreased obviously in HF group (P < 0.05), LVDP increased (P < 0.05). Compared with HF group, the LVSP, +dP/dtmax and − dP/dtmax of Ghrelin group was remarkedly increased (P < 0.05), LVDP decreased (P < 0.05), indicating that Ghrelin significantly improved the hemodynamic status of rats with HF.

Fig. 3 Comparison of cardiac hemodynamics in different groups. Note: LVSP, Left ventricular systolic pressure; LVDP, Left ventricular diastolic pressure; +dP/dtmax, maximum rate of increase in left ventricular pressure; − dP/dtmax, maximum rate of decrease in left ventricular pressure. Compared with HF group, * P < 0.05; Compared with control group, #P < 0.05

Myocardial morphological and histological changes

Figure 4 presented that under the light microscope, in the control group, the cardiomyocytes were arranged neatly, the nuclei were clear, the transverse lines were clear, the cell space was normal, there was no cell degeneration and necrosis, and there was no inflammatory exudation in the interstitial tissue. In the HF group, the cardiomyocytes lost normal morphological structure, the cardiomyocytes were arranged irregularly, and some of them showed degeneration, dissolution and necrosis, the gap between cardiomyocytes widened, and inflammatory cells infiltrated in the interstitium. The myocardial tissue injury in Ghrelin group was significantly less than that in HF group.

Fig. 4 The HE staining image of myocardium (400 ×). Note: The black indicates infiltration of inflammatory cells, the green indicates uneven alignment of cardiomyocytes and widening of gaps

Comparison of serum levels of TNF-α, IL-10 and iNOS

Figures 5, 6 and 7 depicted compared with control group, the serum TNF-α and iNOS levels of HF group rats were prominently increased, IL-10 decreased (P < 0.05). The levels of TNF-α and iNOS in Ghrelin group were notably lower than those in HF group (P < 0.05), the IL-10 level increased markedly (P < 0.05), indicating that Ghrelin significantly improved the inflammatory response in rats with HF.

Fig. 5 Comparison of serum TNF-α, IL-10 and iNOS level in different groups. Note: Compared with HF group, * P < 0.05; Compared with control group, #P < 0.05

Fig. 6 The protein expression of TNF-α, IL-10 and iNOS.. Note: Compared with HF group, * P < 0.05; Compared with control group, #P < 0.05

Fig. 7 The immunohistochemical results of TNF-α, IL-10 and iNOS (200 ×). Note: Compared with HF group, * P < 0.05; Compared with control group, #P < 0.05

Discussion

Dox is an anthraquinone-based antitumor chemotherapeutic agent, which is clinically used in the treatment of various solid tumors and hematological tumors. However, its clinical application is limited by its severe cardiotoxic effects [20]. The pathological features of Dox-induced cardiomyopathy are similar to those of dilated cardiomyopathy, including apoptosis, mitochondrial swelling, disturbances in energy metabolism in cardiomyocytes and accumulation of oxygen free radicals (ROS). However, it was found that the inhibition of ROS aggregation did not ameliorate the toxic effects of Dox on the heart, so it was hypothesized that multiple factors and pathways would be required to achieve a primary effect [21, 22]. Our study indicated that Ghrelin had a certain protective effect on Dox-induced myocardial injury in rats, which could improve the contractile function of the heart, inhibit the necrosis of cardiomyocytes and regulate the expression of circulating inflammatory factors to a certain extent.

Ghrelin is synthesized and secreted mainly from the digestive tract, but its receptors are expressed in various tissues and organs of the body. Ghrelin plays a key role in the regulation of food intake and energy balance [23]. In addition, Ghrelin can act on myocardial tissue in both healthy and cardiac individuals. It has been shown that plasma Ghrelin levels are obviously higher in patients with CHF than in healthy individuals, and the Ghrelin levels decrease after heart transplantation. Meanwhile, Ghrelin may improve cardiac function and cardiac output in CHF patients by promoting the release of growth hormone from the pituitary gland and directly stimulating the GHS-R [24, 25]. In a study of healthy adults, it was confirmed that the administration of double human physiological dose of Ghrelin can apparently improve cardiac index (CI) and cardiac stroke volume index (SVI), and reduce peripheral vascular resistance. The previous studies in animal models also found that the administration of exogenous Ghrelin in rats with dilated cardiomyopathy can reduce left ventricular end-diastolic volume and increase LVEF, and improve the 30-day survival rate of rats [26]. Our study also found that Ghrelin partially improved cardiac hemodynamic parameters in rats with HF, which was consistent with the results of Çetin’s study [27]. On the other hand, Ghrelin inhibited sympathetic nerve activity and activated parasympathetic nerve activity in healthy subjects, which may partly explain why Ghrelin improved survival in rats with dilated cardiomyopathy [28]. Our study also demonstrated that exogenous Ghrelin administration in rats with drug-toxic cardiomyopathy histologically ameliorated cardiomyocyte injury, reduced LVDD and LVSD, and increased LVEF.

CHF is a chronic inflammatory state manifested by elevated plasma levels of the inflammatory factor TNF-α and activation of the renin-angiotensin system [29]. Ghrelin inhibits the excessive production of oxygenation stress products by vascular endothelial cells and activation of the enzyme NADPH oxidase, as well as the production of pro-inflammatory cytokines by inhibiting the activation of NF - κB [30]. In a study of heart-lung transplant recipients, Ghrelin was found to be cardioprotective by decreasing circulating levels of TNF-α, IL-6 and myeloperoxidase activation. These inflammatory cytokines of TNF-α and IL-6 can activate the expression of iNOS in myocardial tissue [31, 32]. As an anti-inflammatory cytokine, IL-10 can inhibit the inflammatory cytokines produced in the process of congestive HF, which can directly combat the damage of myocardium mediated by inflammatory cytokines and has a protective effect on the heart [33]. In our study, we found that Ghrelin increased the expression of IL-10, decreased the expression of TNF-α and iNOS, suggesting that Ghrelin may play a role in improving cardiac function in rats with HF, which was consistent with the results of Erhardsson’s study [25]. Recently, Ghrelin was found to inhibit the development of ischemia-reperfusion-induced hepatic fibrosis by regulating the matrix metalloproteinase tissue inhibitor pathway and inducing the degradation of hepatic extracellular matrix (ECM), and it is hypothesized that Ghrelin may have a similar beneficial effect on the heart, which has yet to be confirmed in further studies. Previous studies have suggested that Ghrelin attenuated Dox-induced cardiotoxicity in mice by affecting the AMPK and p38-MAPK signaling pathways [34, 35]. Therefore, our study suggested that Ghrelin played a protective role in Dox induced myocardial injury and HF through various mechanisms. Our study has some limitations. For example, the molecular mechanism is not explored deeply enough. In future studies, single-cell sequencing of Ghrelin and HF groups could be performed to better understand how different heart cells respond to Ghrelin treatment.

Conclusion

Ghrelin protects Dox from cardiac muscle damage and improves cardiac function in rats. This provides a new way to study the beneficial effects of Ghrelin on the prevention and treatment of cardiomyopathy caused by drug toxicity.

Acknowledgements

Not applicable.

Author contributions

YP is resposible for the guarantor of integrity of the entire study, definition of intellectual content, clinical studies, experimental studies, data acquisition, statistical analysis, manuscript review; PZ is resposible for the study concepts & design, literature research, data acquisition, manuscript editing; PTZ is resposible for the guarantor of integrity of the entire study, literature research, experimental studies, data analysis, manuscript preparation; YXZ is resposible for the study concepts, definition of intellectual content, clinical studies, data analysis; LS is resposible for the study design, statistical analysis, manuscript preparation & review. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No.82260078, for Shao Liang); Interventional Therapy Clinical Medical Research Center of Jiangxi Province (No.20223BCG74005); the Science and Technology Plan of Jiangxi Provincial Health Commission (No.202410137 for Shao Liang).

Data availability

All data generated or analysed during this study are included in this. Further enquiries can be directed to the corresponding author.

Declarations

Ethics approval and consent to participate

The study was approved by the Jiangxi Provincial People’s Hospital, the First Affiliated Hospital of Nanchang Medical College.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Conflict of interest

There are no potential conflicts of interest to disclose.

Abbreviations

Dox Doxorubicin

HF Heart failure

CHF Chronic Heart Failure

GHSR Growth Hormone Secretagogue Receptor

LVDD Left ventricular end-diastolic diameter

LVSD Left ventricular end-systolic diameter

LVEF Left ventricular ejection fraction

LVFS Left ventricular short axis shortening rate

LVSP Left ventricular systolic pressure

LVDP Left ventricular diastolic pressure

ROS Oxygen free radicals

CI Cardiac index

SVI Stroke volume index

ECM Extracellular matrix

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Roger VL Epidemiology of heart failure: a contemporary perspective Circ Res 2021 128 10 1421 34 10.1161/CIRCRESAHA.121.318172 33983838
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–34. 10.1161/CIRCRESAHA.121.318172.33983838 10.1161/CIRCRESAHA.121.318172
2. Lippi G Sanchis-Gomar F Global epidemiology and future trends of heart failure AME Med J 2020 10.21037/amj.2020.03.03
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020. 10.21037/amj.2020.03.03.10.21037/amj.2020.03.03
3. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, SeferoviĆ P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021:S1071-9164(21)00050 – 6. 10.1016/j.cardfail.2021.01.022
4. Jenča D Melenovský V Stehlik J Staněk V Kettner J Kautzner J Adámková V Wohlfahrt P Heart failure after myocardial infarction: incidence and predictors ESC Heart Fail 2021 8 1 222 37 10.1002/ehf2.13144 33319509
Jenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J, Adámková V, Wohlfahrt P. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8(1):222–37. 10.1002/ehf2.13144.33319509 10.1002/ehf2.13144
5. Melendo-Viu M Abu-Assi E Manzano-Fernández S Flores-Blanco P Cambronero-Sánchez F Pérez DD Fernández MC Galian MJS Molina MG Caneiro-Queija B Paz RC Pousa IM Valdes M Figal DP Iíguez-Romo A Incidence, prognosis and predictors of heart failure after acute myocardial infarction REC: CardioClinics 2020 55 1 8 14 10.1016/j.rccl.2019.08.001
Melendo-Viu M, Abu-Assi E, Manzano-Fernández S, Flores-Blanco P, Cambronero-Sánchez F, Pérez DD, Fernández MC, Galian MJS, Molina MG, Caneiro-Queija B, Paz RC, Pousa IM, Valdes M, Figal DP, Iíguez-Romo A. Incidence, prognosis and predictors of heart failure after acute myocardial infarction. REC: CardioClinics. 2020;55(1):8–14. 10.1016/j.rccl.2019.08.001.10.1016/j.rccl.2019.08.001
6. Sinha SS Rosner CM Tehrani BN Maini A Truesdell AG Lee SB Bagchi P Cameron J Damluji AA Desai M Desai SS Epps KC deFilippi C Flanagan MC Genovese L Moukhachen H Park JJ Psotka MA Raja A Shah P Sherwood MW Singh R Tang D Young KD Welch T O’Connor CM Batchelor WB Cardiogenic shock from heart failure Versus Acute myocardial infarction: clinical characteristics, Hospital Course, and 1-Year outcomes Circ Heart Fail 2022 15 6 e009279 10.1161/CIRCHEARTFAILURE.121.009279 35510546
Sinha SS, Rosner CM, Tehrani BN, Maini A, Truesdell AG, Lee SB, Bagchi P, Cameron J, Damluji AA, Desai M, Desai SS, Epps KC, deFilippi C, Flanagan MC, Genovese L, Moukhachen H, Park JJ, Psotka MA, Raja A, Shah P, Sherwood MW, Singh R, Tang D, Young KD, Welch T, O’Connor CM, Batchelor WB. Cardiogenic shock from heart failure Versus Acute myocardial infarction: clinical characteristics, Hospital Course, and 1-Year outcomes. Circ Heart Fail. 2022;15(6):e009279. 10.1161/CIRCHEARTFAILURE.121.009279.35510546 10.1161/CIRCHEARTFAILURE.121.009279
7. Ghionzoli N Gentile F Del Franco AM Castiglione V Aimo A Giannoni A Burchielli S Cameli M Emdin M Vergaro G Current and emerging drug targets in heart failure treatment Heart Fail Rev 2022 27 4 1119 36 10.1007/s10741-021-10137-2 34273070
Ghionzoli N, Gentile F, Del Franco AM, Castiglione V, Aimo A, Giannoni A, Burchielli S, Cameli M, Emdin M, Vergaro G. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2022;27(4):1119–36. 10.1007/s10741-021-10137-2.34273070 10.1007/s10741-021-10137-2
8. Kciuk M Gielecińska A Mujwar S Kołat D Kałuzińska-Kołat Ż Celik I Kontek R Doxorubicin-An Agent with multiple mechanisms of Anticancer Activity Cells 2023 12 4 659 10.3390/cells12040659 36831326
Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, Kontek R. Doxorubicin-An Agent with multiple mechanisms of Anticancer Activity. Cells. 2023;12(4):659. 10.3390/cells12040659.36831326 10.3390/cells12040659
9. Kalyanaraman B Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol 2020 29 101394 10.1016/j.redox.2019.101394 31790851
Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol. 2020;29:101394. 10.1016/j.redox.2019.101394.31790851 10.1016/j.redox.2019.101394
10. Rawat PS Jaiswal A Khurana A Bhatti JS Navik U Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management Biomed Pharmacother 2021 139 111708 10.1016/j.biopha.2021.111708 34243633
Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. 10.1016/j.biopha.2021.111708.34243633 10.1016/j.biopha.2021.111708
11. Songbo M Lang H Xinyong C Bin X Ping Z Liang S Oxidative stress injury in doxorubicin-induced cardiotoxicity Toxicol Lett 2019 307 41 8 10.1016/j.toxlet.2019.02.013 30817977
Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41–8. 10.1016/j.toxlet.2019.02.013.30817977 10.1016/j.toxlet.2019.02.013
12. Date Y Kojima M Hosoda H Sawaguchi A Mondal MS Suganuma T Matsukura S Kangawa K Nakazato M Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans Endocrinology 2000 141 11 4255 61 10.1210/endo.141.11.7757 11089560
Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141(11):4255–61. 10.1210/endo.141.11.7757.11089560 10.1210/endo.141.11.7757
13. Ishida J Saitoh M Ebner N Springer J Anker SD von Haehling S Growth hormone secretagogues: history, mechanism of action, and clinical development JCSM Rapid Commun 2020 3 1 25 37 10.1002/rco2.9
Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25–37.10.1002/rco2.9
14. Trippel TD et al. Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study, ESC heart failure, 4, 1, pp. 56–65, 2017. 10.1002/ehf2.12109
15. Mehdar K The distribution of ghrelin cells in the human and animal gastrointestinal tract: a review of the evidence Folia Morphol (Warsz) 2021 80 2 225 36 10.5603/FM.a2020.0077 32644180
Mehdar K. The distribution of ghrelin cells in the human and animal gastrointestinal tract: a review of the evidence. Folia Morphol (Warsz). 2021;80(2):225–36. 10.5603/FM.a2020.0077.32644180 10.5603/FM.a2020.0077
16. El-Shaer N, El Gazzar WB, Allam MM, Anwer HM. Ghrelin ameliorated inflammation and oxidative stress in isoproterenol induced myocardial infarction through the endothelial nitric oxide synthase (eNOS)/nuclear factor erythroid 2-related factor-2 (NRF2)/heme oxygenase-1 (HO-1) signaling pathway. J Physiol Pharmacol. 2021;72(2). 10.26402/jpp.2021.2.12.
17. Khatib MN Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis PLoS ONE 2015 10 5 e0126697 10.1371/journal.pone.0126697 26016489
Khatib MN, et al. Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PLoS ONE. 2015;10(5):e0126697. 10.1371/journal.pone.0126697.26016489 10.1371/journal.pone.0126697
18. Nasrallah C. Effect of a naturally occurring ghrelin splice variant on Substantia Nigra dopamine neurons. Yale University; 2018.
19. Xu A NF-κB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity Biomed Pharmacother 2020 130 110525 10.1016/j.biopha.2020.110525 32702633
Xu A, et al. NF-κB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2020;130:110525. 10.1016/j.biopha.2020.110525.32702633 10.1016/j.biopha.2020.110525
20. Wenningmann N Knapp M Ande A Vaidya TR Ait-Oudhia S Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring Mol Pharmacol 2019 96 2 219 32 10.1124/mol.119.115725 31164387
Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S. Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol. 2019;96(2):219–32. 10.1124/mol.119.115725.31164387 10.1124/mol.119.115725
21. Zhang S Wei X Zhang H Wu Y Jing J Huang R Zhou T Hu J Wu Y Li Y You Z Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway Biomed Pharmacother 2023 162 114691 10.1016/j.biopha.2023.114691 37060659
Zhang S, Wei X, Zhang H, Wu Y, Jing J, Huang R, Zhou T, Hu J, Wu Y, Li Y, You Z. Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway. Biomed Pharmacother. 2023;162:114691. 10.1016/j.biopha.2023.114691.37060659 10.1016/j.biopha.2023.114691
22. Shi S Chen Y Luo Z Nie G Dai Y Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy Cell Commun Signal 2023 21 1 61 10.1186/s12964-023-01077-5 36918950
Shi S, Chen Y, Luo Z, Nie G, Dai Y. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun Signal. 2023;21(1):61. 10.1186/s12964-023-01077-5.36918950 10.1186/s12964-023-01077-5
23. Ringuet MT Koo A Furness SGB McDougall SJ Furness JB Sites and mechanisms of action of colokinetics at dopamine, ghrelin and serotonin receptors in the rodent lumbosacral defecation centre J Physiol 2023 601 23 5195 211 10.1113/JP285217 37772438
Ringuet MT, Koo A, Furness SGB, McDougall SJ, Furness JB. Sites and mechanisms of action of colokinetics at dopamine, ghrelin and serotonin receptors in the rodent lumbosacral defecation centre. J Physiol. 2023;601(23):5195–211. 10.1113/JP285217.37772438 10.1113/JP285217
24. Yuan MJ Li W Zhong P Research progress of ghrelin on cardiovascular disease Biosci Rep 2021 41 1 BSR20203387 10.1042/BSR20203387 33427286
Yuan MJ, Li W, Zhong P. Research progress of ghrelin on cardiovascular disease. Biosci Rep. 2021;41(1):BSR20203387. 10.1042/BSR20203387.33427286 10.1042/BSR20203387
25. Erhardsson M Faxén UL Venkateshvaran A Hage C Pironti G Thorvaldsen T Webb DL Hellström PM Andersson DC Ståhlberg M Lund LH Acyl ghrelin increases cardiac output while preserving right ventricular-pulmonary arterial coupling in heart failure ESC Heart Fail 2024 11 1 601 5 10.1002/ehf2.14580 38030138
Erhardsson M, Faxén UL, Venkateshvaran A, Hage C, Pironti G, Thorvaldsen T, Webb DL, Hellström PM, Andersson DC, Ståhlberg M, Lund LH. Acyl ghrelin increases cardiac output while preserving right ventricular-pulmonary arterial coupling in heart failure. ESC Heart Fail. 2024;11(1):601–5. 10.1002/ehf2.14580.38030138 10.1002/ehf2.14580
26. Du CK Zhan DY Morimoto S Akiyama T Schwenke DO Hosoda H Kangawa K Shirai M Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy Pharmacol Res Perspect 2014 2 5 e00064 10.1002/prp2.64 25505608
Du CK, Zhan DY, Morimoto S, Akiyama T, Schwenke DO, Hosoda H, Kangawa K, Shirai M. Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy. Pharmacol Res Perspect. 2014;2(5):e00064. 10.1002/prp2.64.25505608 10.1002/prp2.64
27. Çetin E Protective effect of ghrelin against tilmicosin-induced left ventricular dysfunction in rats Can J Physiol Pharmacol 2019 97 5 407 12 10.1139/cjpp-2018-0511 30726105
Çetin E. Protective effect of ghrelin against tilmicosin-induced left ventricular dysfunction in rats. Can J Physiol Pharmacol. 2019;97(5):407–12. 10.1139/cjpp-2018-0511.30726105 10.1139/cjpp-2018-0511
28. Aleksova A Beltrami AP Bevilacqua E Padoan L Santon D Biondi F Barbati G Stenner E Gortan Cappellari G Barazzoni R Ziberna F Zwas DR Avraham Y Agostoni P Not T Livi U Sinagra G Ghrelin derangements in idiopathic dilated cardiomyopathy: impact of myocardial Disease Duration and Left Ventricular Ejection Fraction J Clin Med 2019 8 8 1152 10.3390/jcm8081152 31375017
Aleksova A, Beltrami AP, Bevilacqua E, Padoan L, Santon D, Biondi F, Barbati G, Stenner E, Gortan Cappellari G, Barazzoni R, Ziberna F, Zwas DR, Avraham Y, Agostoni P, Not T, Livi U, Sinagra G. Ghrelin derangements in idiopathic dilated cardiomyopathy: impact of myocardial Disease Duration and Left Ventricular Ejection Fraction. J Clin Med. 2019;8(8):1152. 10.3390/jcm8081152.31375017 10.3390/jcm8081152
29. Aimo A Castiglione V Borrelli C Saccaro LF Franzini M Masi S Emdin M Giannoni A Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies Eur J Prev Cardiol 2020 27 5 494 510 10.1177/2047487319870344 31412712
Aimo A, Castiglione V, Borrelli C, Saccaro LF, Franzini M, Masi S, Emdin M, Giannoni A. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020;27(5):494–510. 10.1177/2047487319870344.31412712 10.1177/2047487319870344
30. Wang Q Liu AD Li TS Tang Q Wang XC Chen XB Ghrelin ameliorates cardiac fibrosis after myocardial infarction by regulating the Nrf2/NADPH/ROS pathway Peptides 2021 144 170613 10.1016/j.peptides.2021.170613 34314760
Wang Q, Liu AD, Li TS, Tang Q, Wang XC, Chen XB. Ghrelin ameliorates cardiac fibrosis after myocardial infarction by regulating the Nrf2/NADPH/ROS pathway. Peptides. 2021;144:170613. 10.1016/j.peptides.2021.170613.34314760 10.1016/j.peptides.2021.170613
31. Sun N Mei Y Hu Z Xing W Lv K Hu N Zhang T Wang D Ghrelin attenuates depressive-like behavior, heart failure, and neuroinflammation in postmyocardial infarction rat model Eur J Pharmacol 2021 901 174096 10.1016/j.ejphar.2021.174096 33848542
Sun N, Mei Y, Hu Z, Xing W, Lv K, Hu N, Zhang T, Wang D. Ghrelin attenuates depressive-like behavior, heart failure, and neuroinflammation in postmyocardial infarction rat model. Eur J Pharmacol. 2021;901:174096. 10.1016/j.ejphar.2021.174096.33848542 10.1016/j.ejphar.2021.174096
32. Zheng H Liang W He W Huang C Chen Q Yi H Long L Deng Y Zeng M Ghrelin attenuates sepsis-induced acute lung injury by inhibiting the NF-κB, iNOS, and akt signaling in alveolar macrophages Am J Physiol Lung Cell Mol Physiol 2019 317 3 L381 91 10.1152/ajplung.00253.2018 31242025
Zheng H, Liang W, He W, Huang C, Chen Q, Yi H, Long L, Deng Y, Zeng M. Ghrelin attenuates sepsis-induced acute lung injury by inhibiting the NF-κB, iNOS, and akt signaling in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2019;317(3):L381–91. 10.1152/ajplung.00253.2018.31242025 10.1152/ajplung.00253.2018
33. Sandek A Gertler C Valentova M Jauert N Wallbach M Doehner W von Haehling S Anker SD Fielitz J Volk HD Increased expression of proinflammatory genes in peripheral blood cells is Associated with Cardiac Cachexia in patients with heart failure with reduced ejection fraction J Clin Med 2024 13 3 733 10.3390/jcm13030733 38337428
Sandek A, Gertler C, Valentova M, Jauert N, Wallbach M, Doehner W, von Haehling S, Anker SD, Fielitz J, Volk HD. Increased expression of proinflammatory genes in peripheral blood cells is Associated with Cardiac Cachexia in patients with heart failure with reduced ejection fraction. J Clin Med. 2024;13(3):733. 10.3390/jcm13030733.38337428 10.3390/jcm13030733
34. Chen Y Wang H Zhang Y Wang Z Liu S Cui L Pretreatment of ghrelin protects H9c2 cells against hypoxia/reoxygenation-induced cell death via PI3K/AKT and AMPK pathways Artif Cells Nanomed Biotechnol 2019 47 1 2179 87 10.1080/21691401.2019.1620253 31159591
Chen Y, Wang H, Zhang Y, Wang Z, Liu S, Cui L. Pretreatment of ghrelin protects H9c2 cells against hypoxia/reoxygenation-induced cell death via PI3K/AKT and AMPK pathways. Artif Cells Nanomed Biotechnol. 2019;47(1):2179–87. 10.1080/21691401.2019.1620253.31159591 10.1080/21691401.2019.1620253
35. Perpétuo L Voisin PM Amado F Hirtz C Vitorino R Ghrelin and adipokines: an overview of their physiological role, antimicrobial activity and impact on cardiovascular conditions Vitam Horm 2021 115 477 509 10.1016/bs.vh.2020.12.019 33706959
Perpétuo L, Voisin PM, Amado F, Hirtz C, Vitorino R. Ghrelin and adipokines: an overview of their physiological role, antimicrobial activity and impact on cardiovascular conditions. Vitam Horm. 2021;115:477–509. 10.1016/bs.vh.2020.12.019.33706959 10.1016/bs.vh.2020.12.019
